Tomasz RL

Language: Spanish
References: 11
Page: 177-183
PDF size: 77.81 Kb.

ABSTRACT

Objectives: The assessment of therapeutic effects of paroxetyne in major depression syndrome using the psychological scales and patients’ psychiatric treatment.
Methods: The group chosen for the study consisted of 99 patients treated with paroxetyne due to a major depression syndrome. The control group consisted of 98 patients treated with Sulpiride due to a major depression syndrome. Data for the study were taken from the diseases history of the persons. All patients were carefully diagnosed according to 24 points Hamilton Depression Evaluation Scale, Beck Depression Self-Assessment Inventory and Montgomery-Asberg Scale. The effects of the treatment were assessed using the those scales and patients’ psychiatric treatment.
Results: Generally good effects of the treatment were observed for approximately 80% off all patients treated with paroxetyna. Average results after treatment decreased from 46.2 points to 17.4 points in Hamilton Depression Evaluation Scale. After treatment of major depression with paroxetyne decrease of number of points in Hamilton Scale accounted for 90.6% (light depression), 64.1% (medium depression) and 57.4% (major depression). After treatment with paroxetyne 47.47% patients noted full and fixed remission of the major depression syndrome, 6.06% of patients noted significant improvement, 20.20% noted medium improvement and 6.06% noted only poor improvement in major depression disease. Based on Montgomery-Asberg Scale approximately 47% patients noted full and fixed remission of the major depression syndrome, 6% of patients noted significant improvement, 20% noted medium improvement and 6% noted only poor improvement in major depression disease.
Conclusions: The improvement was noted for the significant share of 80% of all patients treated with paroxetyne. The treatment resulted in average decrease of number of points in Hamilton Depression Evaluation Scale from 46.2 points to 17.4 points. In the light depression syndrome the treatment with Paroxetyne resulted in the remission of 90.6% of the depression symptoms in Hamilton Depression Evaluation Scale and 91.2% of the depression symptoms in Beck Depression Self-Assessment Inventory.

REFERENCES

1. Farmacología de los inhibidores selectivos de la recaptación de la serotonina (SSRIs). Pharmacology of selective serotonin reuptake inhibitors (SSRIs). [Aut] El|bieta Czarnecka, JarosBaw Strzelec. Farm Pol 2001; 57(13): 603-612, il., bibliogr. 46 ítem, sum.

2. Ridout F, Meadows R, Johnsen S, Hindmarch I. Evaluación de efectos de paroxetina y mitrazapina controlada con placebo en los resultados de estudios ligados a la habilidad para conducir máquinas (A placebo controlled investigation into the effects of paroxetine and mitrazapine on measures related to car driving performance). Human Psychopharmacology 2003;18(4):261-9.

3. Serretti A, Zanardi R, Cusin C, Rossini D. Gen de hidroxilasa de triptófano asociado a la actividad antidepresiva de la Paroxetina (Tryptophan hydroxylase gene associated with paroxetine antidepressant activity). European Neuropsychopharmacology 2001;11(5):375-80.

4. Sargent PA, Williamson DJ, Cowen PJ. Neurotransmisión cerebral de 5-HT durante el tratamiento con Paroxetina (Brain 5-HT neurotransmission during paroxetine treatment). British Journal of Psychiatry 1998;172: 49-52.

5. Keller MB. El tratamiento de depresión mayor con Paroxetina (Paroxetine treatment of major depressive disorder). Psychopharmacology Bulletin 2003;37 Suppl. 1: 42-52, Spring.

6. Szegedi A, Muller MJ, Anghelescu I. Una mejoría temprana como consecuencia del uso de mitrazapina y Paroxetina predice con gran exactitud una posterior respuesta estable y remisión en pacientes con depresión mayor (Early improvement under mitrazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression). Journal of Clinical Psychiatry 2003;64(4):413-20.

7. Braconnier A, Le Coent R, Cohen D. Paroxetina versus clomipramina en adolescentes con depresión mayor: estudios randomizados multicéntricos dobles ciegos (Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind randomized, multicenter trial). Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(1): 22-9.

8. Chandhry HR, Qureshi Z, Tareen IA. Eficacia y tolerancia de la paroxetina 20 mg diarios en el tratamiento de la depresión y angustia relacionada con la depresión (Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety). JPMA – Journal of the Pakistan Medical Association 2002;52(11): 518-25.

9. Waintraub L, Septien L, Azoukay P. Eficacia y seguridad de la tianeptina en depresión mayor: evidencias del estudio clínico controlado de 3 meses versus Paroxetina (Efficacy and safety of traneptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetine). CNS Drugs 2002;16(1): 65-75.

10. Montgomery SA. Meta-análisis de eficacia y tolerancia de la Paroxetina versus fármacos antidepresivos tricíclicos en el tratamiento de depresión mayor (A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression). International Clinical Psychopharmacology 2001;16(3):169-78.

11. Hawley CJ, Pattinson HA, Quick SJ. Protocolo para el tratamiento farmacológico de depresión mayor. Test de campo abierto del prototipo potencial (A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype). Journal of Affective Disorders 1998;47(1-3):87-96